title: Scedosporium Keratitis: An Experience From a Tertiary Eye Hospital in South India.
abstract: OBJECTIVE
  To determine the clinical profile and prognosis of Scedosporium keratitis.
  
  
  METHODS
  All culture-proven cases were retrospectively analyzed for demographics, clinical characteristics, treatment offered, and resolution time with sequel.
  
  
  RESULTS
  Among the 1792 culture-proven fungal keratitis cases in the study period, 10 (0.6%) were the result of Scedosporium. The mean age of patients was 44.2 years. Eight patients were male. A history of trauma was present in 8 patients. The infiltrate involved the center of the cornea in 5 patients, whereas 4 patients had paracentral involvement and 1 patient had limbal involvement. The mean maximum diameter of infiltrate was 3.4 mm. Five cases were prescribed topical natamycin alone: 4 patients were successfully treated with this monotherapy, whereas 1 patient was lost to follow-up, but the records of the last visit revealed healing. Three patients were treated with a combination therapy of topical natamycin and 1% voriconazole: 2 patients showed complete healing of the ulcer, and 1 patient progressed to corneal perforation necessitating penetrating keratoplasty.
  
  
  CONCLUSIONS
  To our knowledge, this is the largest case series on Scedosporium keratitis to date. This is the first study to report successful treatment of this infection with topical natamycin monotherapy. The outcome may improve if appropriate medical therapy is started early.
authors.affiliation: Aravind Eye Hospital and Post graduate Institute of Ophthalmology, Tirunelveli, India.
authors.forename: Harshal Shrikant
authors.initials: HS
authors.lastname: Rathi
authors.forename: Anitha
authors.initials: A
authors.lastname: Venugopal
authors.forename: Ramakrishnan
authors.initials: R
authors.lastname: Rengappa
authors.forename: Meenakshi
authors.initials: M
authors.lastname: Ravindran
mesh_terms: D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use; D003320:Corneal Ulcer / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D004359:Drug Therapy, Combination; D015821:Eye Infections, Fungal / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D006782:Hospitals, Special; D006801:Humans; D007194:India; D015948:Keratoplasty, Penetrating; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D010866:Natamycin / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D009885:Ophthalmology; D011379:Prognosis; D012189:Retrospective Studies; D021681:Scedosporium / Q000302:isolation & purification*; D062606:Tertiary Care Centers; D014792:Visual Acuity; D065819:Voriconazole / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D009883:Ophthalmic Solutions; D010866:Natamycin; D065819:Voriconazole